Evogene
 | This article contains promotional content. (May 2022) |
 | |
| Company type | Public |
|---|---|
| TASE: EVGN NYSE: EVGN | |
| Industry | Computational Biology |
| Founded | 2002 |
| Founder | Dr. Hagai Karchi and Dr. Rafi Meissner |
| Headquarters | Rehovot, Israel |
Key people | Sarit Firon, Chairperson of Board, Ofer Haviv, President & CEO |
| Subsidiaries | Biomica, Canonic, Lavie Bio, AgPlenus, Castera |
| Website | www |
Evogene is a computational biology company based in Israel.[1] Evogene Ltd. (NASDAQ:EVGN) has developed a unique computational predictive biology "CPB" platform, which leverages big data with advanced algorithms such as machine learning and other artificial intelligence (AI), while adding a deep understanding of biology and advanced biological technologies.[2] Evogene is using its proprietary CPB platform to computationally design and develop next-generation life-science products based upon three core components: microbes, small molecules, and genetic elements.
Evogene's computational platform allows it to substantially increase the probability of successful life-science product development, increase the efficiency and reduce the toxicity of its life-science products while reducing time and cost to development. Its strategic partners include BASF (OTCQX:BASFY), Bayer (OTCPK:BAYZF), Corteva (CTVA), ICL Group Ltd. (ICL) as well as various academic and medical institutions.
References
[edit]- ^ "דף הבית - הבורסה לניירות ערך בתל אביב | אתר הבורסה". market.tase.co.il. Retrieved 2024-12-08.
- ^ Evogene. "Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design". www.prnewswire.com. Retrieved 2024-12-08.
 | This article about a corporation or company specializing in health technology is a stub. You can help Wikipedia by expanding it. |
  | This article about an Israeli company is a stub. You can help Wikipedia by expanding it. |